2 diabetes drugs up for FDA safety review in April

03/9/2009 | CNNMoney

An FDA advisory committee is scheduled next month to examine whether Bristol-Myers Squibb's saxagliptin and Novo Nordisk's liraglutide increase the risks of heart attack and stroke in patients with Type 2 diabetes. The move is in line with the agency's guidance issued in December.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC